Solara board approves unaudited September 2026 results; auditor reports no material misstatement identified
As filed · Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter and half year
What happened
FactSolara Active Pharma Sciences’ board approved the standalone and consolidated unaudited financial results for the quarter and six months ended September 30, 2026. Deloitte Haskins & Sells’ limited review report stated that nothing came to its attention indicating the consolidated statement contained a material misstatement or failed to disclose required information.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
Revisedexcluding the ibuprofen business, the base business delivered a 24% growth on this quarter.
if you adjust that particular price increase what we had passed through in terms of revenue growth number, so that growth should be coming around to close to 18%, 19% of year-on-year growth as compared to Q1 of '26.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- the strategic review of the ibuprofen business would be concluded by the first half of '27. (management committed by H1 FY27)
- we will come up with the next steps in terms of both ibuprofen Vizag, Pondy and what we do with the CRAMS deme (management committed by Q2 FY27)
Evidence
- Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026, along with the Limited Review Report for the said period.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- The filing confirms board approval of the period’s financial results and an unmodified limited-review conclusion. However, the supplied text does not include revenue, profit, cash flow, or balance-sheet figures, so the financial performance cannot be assessed from this filing alone.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%